Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$26.04 -1.64%

-$0.38 today

Market cap
$1.81B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 1.02M

Average 0.71M

ZYME Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Zymeworks Inc.NASDAQ: ZYME

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit growth accelerates

Q3 FY2026 gross profit of $177.6M rose 543.1% year over year, ahead of the +35.8% change in trailing-twelve-month gross profit. Sequentially, it rose 3769.2% from the prior quarter. Over 3 fiscal years it compounded at -36.4% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +543.1% holds above the trailing-twelve-month pace of +35.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$177.6M+3769.2% QoQ
Last fiscal yearDec 2025
$105.97M+38.9% YoY
LTMSep 2026
$182.57M+35.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+543.1%——
1 year+38.9%——
3-year CAGR-36.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
105.97M USD
Year-over-year change
+38.9%
4-year CAGR
+41.2%

Gross Profit vs competitors

How ZYME compares with its peers on the latest reported figures

  • ZYME's LTM Sep 2026 gross profit of $182.57M is the 2nd highest of the 11 companies compared; the peer median is $40.38M.
  • Its year-over-year change of +35.8% is the 5th highest of 10, against a peer median of +31.8%.
  • Gross profit amounts to 68.6% of revenue for ZYME, versus a peer median of 89.4%.
ZYME Competitors Peer median
Gross Profit for ZYME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M +545.5%—86.5%
ZYMEZymeworks Inc.LTM Sep 2026$182.57M +35.8%-36.4%68.6%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M +16.2%-9.3%69.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$71.82M +2.1%-29.1%90.7%
CGENCompugen Ltd.LTM Mar 2026$63.98M +230.5%+113.5%88.1%
XNCRXencor, Inc.LTM Jun 2026$45.46M -54.8%—43.3%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$35.29M -76.1%+12.8%99.3%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$11.88M —+424.9%100.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$150K +31.8%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$742K +99.6%—662.5%
IMNMImmunome, Inc.LTM Sep 2026-$753K +98.1%——
Peer median (excluding ZYME) $40.38M+31.8%+12.8%89.4%

Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue26.68M412.48M76.01M76.3M105.97M
Cost of Revenue00142.99M00
Gross Profit26.68M412.48M(66.98M)76.3M105.97M
Gross Margin100.0%100.0%-88.1%100.0%100.0%
Research & Development199.75M208.6M143.62M134.62M137M
Selling, General & Admin42.6M73.4M70.4M61.5M61.5M
Operating Expenses242.31M281.95M71.08M213.41M198.5M
Depreciation & Amortization9.58M12M17.31M11.19M11.11M
EBITDA(206.09M)142.49M(120.7M)(108.62M)(68.64M)
EBITDA Margin-772.4%34.5%-158.8%-142.4%-64.8%
Operating Income(215.63M)130.53M(138.05M)(137.11M)(92.54M)
Operating Margin-808.2%31.6%-181.6%-179.7%-87.3%
Interest Income1.97M3.6M19.71M19.94M13.35M
Interest Expense00000
Other Income / Expenses3.27M4.71M18.81M20.5M12.78M
Income Before Tax(212.36M)135.23M(119.24M)(116.61M)(79.75M)
Pre-Tax Margin-795.9%32.8%-156.9%-152.8%-75.3%
Income Tax Expense(516K)10.89M(568K)6.08M1.38M
Net Income(211.84M)124.34M(118.67M)(122.7M)(81.13M)
Net Margin-794.0%30.1%-156.1%-160.8%-76.6%
EPS (Basic)(4.06)1.91(1.72)(1.62)(1.08)
EPS (Diluted)(4.61)1.90(1.72)(1.62)(1.08)
Weighted Avg Shares52.13M65.19M68.86M75.85M75.34M
Weighted Avg Shares (Diluted)52.13M65.25M68.86M75.88M75.34M

Zymeworks Inc.

NASDAQ:ZYME

Intrinsic Alpha fair value

Locked

Current Price

$26.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.